EP2786140A4 - PACLITAXEL RESPONSE MARKERS FOR CANCER - Google Patents
PACLITAXEL RESPONSE MARKERS FOR CANCERInfo
- Publication number
- EP2786140A4 EP2786140A4 EP12852702.5A EP12852702A EP2786140A4 EP 2786140 A4 EP2786140 A4 EP 2786140A4 EP 12852702 A EP12852702 A EP 12852702A EP 2786140 A4 EP2786140 A4 EP 2786140A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- response markers
- paclitaxel response
- paclitaxel
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563929P | 2011-11-28 | 2011-11-28 | |
| PCT/CA2012/001087 WO2013078537A1 (en) | 2011-11-28 | 2012-11-27 | Paclitaxel response markers for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2786140A1 EP2786140A1 (en) | 2014-10-08 |
| EP2786140A4 true EP2786140A4 (en) | 2015-10-28 |
Family
ID=48534552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP12852702.5A Withdrawn EP2786140A4 (en) | 2011-11-28 | 2012-11-27 | PACLITAXEL RESPONSE MARKERS FOR CANCER |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140349878A1 (en) |
| EP (1) | EP2786140A4 (en) |
| JP (1) | JP2014533955A (en) |
| CN (1) | CN104024851A (en) |
| AU (1) | AU2012344676A1 (en) |
| CA (1) | CA2857191A1 (en) |
| HK (1) | HK1201583A1 (en) |
| WO (1) | WO2013078537A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2525382T3 (en) | 2010-03-31 | 2014-12-23 | Sividon Diagnostics Gmbh | Method for predicting breast cancer recurrence under endocrine treatment |
| US20150376714A1 (en) * | 2013-02-01 | 2015-12-31 | Sividon Diagnostics Gmbh | Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer |
| EP3063689A4 (en) * | 2013-10-29 | 2017-08-30 | Genomic Health, Inc. | Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk |
| EP3158087A4 (en) * | 2014-06-19 | 2018-03-21 | Hidenseq | Polymorphism in the bcl2 gene determines response to chemotherapy |
| MX383691B (en) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | TREATMENT METHOD FOR CANCER ASSOCIATED WITH A RAS MUTATION. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (en) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Method for reducing neutropenia |
| JP2020503363A (en) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | Tubulin binding compounds and their therapeutic use |
| BR112019015974A2 (en) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | METHOD TO REDUCE NEUTROPENY |
| CN107083423B (en) * | 2017-03-27 | 2022-01-28 | 北京极客基因科技有限公司 | Drug target prediction and drug full-range evaluation method |
| EP3679160A4 (en) | 2017-09-08 | 2021-05-19 | Myriad Genetics, Inc. | METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY |
| KR20200112881A (en) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Composition and method for reducing thrombocytopenia through administration of plinabulin |
| MX2021005646A (en) * | 2018-11-14 | 2021-08-11 | Beyondspring Pharmaceuticals Inc | Methods of treating cancer using tubulin binding agents. |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113355419B (en) * | 2021-06-28 | 2022-02-18 | 广州中医药大学(广州中医药研究院) | Breast cancer prognosis risk prediction marker composition and application |
| CN116411072B (en) * | 2022-12-28 | 2023-09-19 | 北京大学第一医院 | A combination of markers for diagnosis and treatment of acral melanoma and its application |
| CN118486374B (en) * | 2024-05-29 | 2025-05-06 | 高精(浙江安吉)精准医学科技有限公司 | Tumor cell identification method based on single-cell sequencing data |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006062811A2 (en) * | 2004-12-08 | 2006-06-15 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
| WO2008006517A2 (en) * | 2006-07-13 | 2008-01-17 | Siemens Healthcare Diagnostics Gmbh | Prediction of breast cancer response to taxane-based chemotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005054814A1 (en) * | 2003-11-26 | 2005-06-16 | Yale University | Apoptosis-based evaluation of chemosensitivity in cancer patients |
| JP5020088B2 (en) * | 2004-11-05 | 2012-09-05 | ジェノミック ヘルス, インコーポレイテッド | Predicting response to chemotherapy using gene expression markers |
| CN101365806B (en) * | 2005-12-01 | 2016-11-16 | 医学预后研究所 | Methods and devices for identifying biomarkers of therapeutic response and use thereof for predicting therapeutic effect |
| CN101424638A (en) * | 2006-09-27 | 2009-05-06 | 广东省人民医院 | Paclitaxel drug curative effect prediction kit and its application |
| DK2297359T3 (en) * | 2008-05-30 | 2014-02-24 | Univ Utah Res Found | Gene expression profiles to predict the outcome of breast cancer |
| WO2010147961A1 (en) * | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US9771618B2 (en) * | 2009-08-19 | 2017-09-26 | Bioarray Genetics, Inc. | Methods for treating breast cancer |
| JPWO2011065533A1 (en) * | 2009-11-30 | 2013-04-18 | 国立大学法人大阪大学 | How to determine sensitivity to breast cancer preoperative chemotherapy |
| ES2364166B1 (en) * | 2009-12-31 | 2012-07-10 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. |
-
2012
- 2012-11-27 CA CA2857191A patent/CA2857191A1/en not_active Abandoned
- 2012-11-27 JP JP2014542653A patent/JP2014533955A/en active Pending
- 2012-11-27 CN CN201280065321.9A patent/CN104024851A/en active Pending
- 2012-11-27 AU AU2012344676A patent/AU2012344676A1/en not_active Abandoned
- 2012-11-27 HK HK15102072.0A patent/HK1201583A1/en unknown
- 2012-11-27 WO PCT/CA2012/001087 patent/WO2013078537A1/en not_active Ceased
- 2012-11-27 US US14/361,153 patent/US20140349878A1/en not_active Abandoned
- 2012-11-27 EP EP12852702.5A patent/EP2786140A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006062811A2 (en) * | 2004-12-08 | 2006-06-15 | Aventis Pharmaceuticals Inc. | Method for measuring resistance or sensitivity to docetaxel |
| WO2008006517A2 (en) * | 2006-07-13 | 2008-01-17 | Siemens Healthcare Diagnostics Gmbh | Prediction of breast cancer response to taxane-based chemotherapy |
Non-Patent Citations (3)
| Title |
|---|
| ANONYMOUS: "Affymetrix GeneChip Human Genome U133 Array Set HG-U133A", GEO, 11 March 2002 (2002-03-11), pages 1 - 4, XP002254749 * |
| IWAO-KOIZUMI K ET AL: "PREDICTION OF DOCETAXEL RESPONSE IN HUMAN BREAST CANCER BY GENE EXPRESSION PROFILING", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 3, 20 January 2005 (2005-01-20), pages 422 - 431, XP009058742, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.09.078 * |
| See also references of WO2013078537A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104024851A (en) | 2014-09-03 |
| US20140349878A1 (en) | 2014-11-27 |
| CA2857191A1 (en) | 2013-06-06 |
| EP2786140A1 (en) | 2014-10-08 |
| HK1201583A1 (en) | 2015-09-04 |
| WO2013078537A1 (en) | 2013-06-06 |
| JP2014533955A (en) | 2014-12-18 |
| AU2012344676A1 (en) | 2014-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2786140A4 (en) | PACLITAXEL RESPONSE MARKERS FOR CANCER | |
| CY2024011I2 (en) | ANTI-FCRN ANTIBODIES | |
| HUS2300021I1 (en) | Anti-IL-36R antibodies | |
| CY2019017I1 (en) | CGRP ANTIBODIES | |
| EP2931922A4 (en) | CUSTOM BIOMARKERS FOR CANCER | |
| EP2750596A4 (en) | INTEGRATED ARCHITECTURES FOR INTEGRATED SYSTEM | |
| EP2718836A4 (en) | DISCOUNT REDIRECTIONS | |
| EP2828405A4 (en) | PANEL OF MARKERS FOR THE DETECTION OF CANCER | |
| EP2834700A4 (en) | PROXIMITY DETECTION FOR FLASH DETECTION | |
| PL2906251T3 (en) | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | |
| EP2751387A4 (en) | SELF-SUSPENDED RETAINING AGENTS FOR HYDRAULIC FRACTURING | |
| EP2708280A4 (en) | MICRORACTOR FOR PHOTORACTIONS | |
| CO6801637A2 (en) | Antibody formulations | |
| EP2847592A4 (en) | FUNCTIONAL SUBSTITUTE DIAGNOSTIC ASSAY FOR CANCER | |
| EP2548549A4 (en) | COMPOSITION FOR EMULSION | |
| EP2920368A4 (en) | VEHICLE FOR GROUND MARKING | |
| BR112014025037A2 (en) | Anti-FGFR2 antibody | |
| BR112013030212A2 (en) | hydraulic deaerator | |
| EP2847355A4 (en) | GENETIC DIAGNOSTIC MARKER GROUP FOR COLORECTAL CANCER | |
| DK2917244T3 (en) | APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES | |
| EP2780480A4 (en) | GAMMA-PNA MINISONDES FOR FLUORESCENT MARKING | |
| EP2686447A4 (en) | PROSTATE CANCER PROGNOSTIC MARKER SETS | |
| DK3521315T3 (en) | Anti-transglutaminase-2 antibodies | |
| DK2828292T3 (en) | JCV-NEUTRALIZING ANTIBODIES | |
| EP2699237A4 (en) | THERAPY FOR LEUKEMIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20140630 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101AFI20150605BHEP Ipc: G01N 33/48 20060101ALI20150605BHEP |
|
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150928 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101AFI20150922BHEP Ipc: G01N 33/48 20060101ALI20150922BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20160527 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20161207 |